Abacus Global Management entered the second quarter of 2026 mid-transformation: once a life-settlement trader that bought, held, and monetized individual insurance policies, it is rebuilding itself as an alternative asset manager, funding that pivot with a buying spree - two insurance brokerages bought in 2025 (National Insurance Brokerage in April, AccuQuote in August), a new longevity dividend fund declared effective weeks after the quarter closed, and a $53 million minority stake in Manning & Napier taken in late May. The quarter that just ended is the clearest snapshot yet of what that pivot does to the numbers, and there are two ways to read it.
The first reads as glowing: total revenue rose 30% to $73.0 million, life-solutions revenue jumped 38%, and adjusted EBITDA hit $39.9 million. The second reads as caution: net income attributable to Abacus fell 62% from $17.6 million to $6.6 million, a swing driven not by the market but by accounting and one-time cost - a fresh, newly adopted method for valuing held life policies, a $7.6 million surge in legal and professional fees tied to in-flight projects, higher stock-based compensation, and the absence of a year-ago warrant gain. What happened and what it means: the headline revenue step-up is real, but a large majority of it is *unrealized* gains on policies still held - a figure that changed meaning the moment the company switched valuation techniques. The test of this business is not this quarter's revenue line; it is whether the operating engine converts into recurring fee income and cash even as the tradeable policy book contracts.
The business is pointed in one direction - toward fee income on other people's capital. Assets under management rose to roughly $3.5 billion across longevity and ETF funds. But the company's own policy portfolio, the asset it actually books on its balance sheet, shrank hard: from 804 life policies at year-end 2025 to 622 at June 30, face value down from $1.06 billion to $683 million, as it sold policies into the funds and securitizations it manages and now charges fees on. The stock trades near $8.92 (52-week range $5.00–$12.44), up sharply off its lows but down about three dollars from the year's high, at a trailing multiple whose only honest reading is on the adjusted numbers, not the GAAP in the headline.